Fig. 2.

Confirmation of rova-IR700 conjugate construction and binding capacity.

(a) Validation of rova-IR700 by SDS-PAGE (left: colloidal blue staining, right: fluorescence at 700 nm). Diluted rovalpituzumab was used as a control.

(b) Immunoblotting with rova-IR700 in lysates from DLL3-overexpressing cells.

(c) Flow cytometric analysis of rova-IR700 in SBC3 and HBEC cells. DLL3 expression in SBC3 cells was evident, while fluorescence was essentially absent in the DLL3-negative HBEC human normal bronchial cells. Prior incubation with excess rovalpituzumab inhibited the binding of rova-IR700 to SBC3 cells, indicating that rova-IR700 binds specifically to DLL3.